These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 23462719)

  • 21. Quantitative measurement of soluble cytokeratin fragments in tissue cytosol of 599 node negative breast cancer patients: a prognostic marker possibly associated with apoptosis.
    Gion M; Boracchi P; Dittadi R; Biganzoli E; Peloso L; Gatti C; Paccagnella A; Rosabian A; Vinante O; Meo S
    Breast Cancer Res Treat; 2000 Feb; 59(3):211-21. PubMed ID: 10832591
    [TBL] [Abstract][Full Text] [Related]  

  • 22. High Ki67/BCL2 index is associated with worse outcome in early stage breast cancer.
    Min KW; Kim DH; Do SI; Pyo JS; Chae SW; Sohn JH; Kim K; Lee HJ; Kim DH; Oh S; Choi SH; Park YL; Park CH; Kwon MJ; Moon KM
    Postgrad Med J; 2016 Dec; 92(1094):707-714. PubMed ID: 27222586
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prognostic molecular markers in women aged 35 years or younger with breast cancer: is there a difference from the older patients?
    Lin CH; Lu YS; Huang CS; Kuo KT; Wang CC; You SL; Lin PH; Chang DY; Kuo WH; Chang KJ; Cheng AL
    J Clin Pathol; 2011 Sep; 64(9):781-7. PubMed ID: 21642658
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A study of ductal versus non-ductal invasive breast carcinomas in older women: long-term clinical outcome and comparison with their younger counterparts.
    Mathew J; Lee S; Syed BM; Morgan DA; Ellis IO; Cheung KL
    Breast Cancer Res Treat; 2014 Oct; 147(3):671-4. PubMed ID: 25148877
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prognostic relevance of basal cytokeratin expression in operable breast cancer.
    Potemski P; Kusinska R; Watala C; Pluciennik E; Bednarek AK; Kordek R
    Oncology; 2005; 69(6):478-85. PubMed ID: 16410686
    [TBL] [Abstract][Full Text] [Related]  

  • 26. High serum HER2 extracellular domain levels: correlation with a worse disease-free survival and overall survival in primary operable breast cancer patients.
    Kong Y; Dai S; Xie X; Xiao X; Lv N; Guo J; Li L; Jia W; Zhang Y; Liu W; Wei W; Xie X
    J Cancer Res Clin Oncol; 2012 Feb; 138(2):275-84. PubMed ID: 22116318
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab.
    Kurebayashi J; Kanomata N; Yamashita T; Shimo T; Mizutoh A; Moriya T; Sonoo H
    Breast Cancer; 2015 May; 22(3):292-9. PubMed ID: 23749689
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Discordance of hormone receptor, human epidermal growth factor receptor-2, and Ki-67 between primary breast cancer and synchronous axillary lymph node metastasis.
    Kinoe H; Yamanouchi K; Kuba S; Morita M; Sakimura C; Kanetaka K; Takatsuki M; Abe K; Yano H; Matsumoto M; Otsubo R; Hayashida N; Nagayasu T; Eguchi S
    J BUON; 2018 Dec; 23(7):60-66. PubMed ID: 30722113
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Molecular subtyping of DCIS: heterogeneity of breast cancer reflected in pre-invasive disease.
    Clark SE; Warwick J; Carpenter R; Bowen RL; Duffy SW; Jones JL
    Br J Cancer; 2011 Jan; 104(1):120-7. PubMed ID: 21139586
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical response after two cycles compared to HER2, Ki-67, p53, and bcl-2 in independently predicting a pathological complete response after preoperative chemotherapy in patients with operable carcinoma of the breast.
    von Minckwitz G; Sinn HP; Raab G; Loibl S; Blohmer JU; Eidtmann H; Hilfrich J; Merkle E; Jackisch C; Costa SD; Caputo A; Kaufmann M;
    Breast Cancer Res; 2008; 10(2):R30. PubMed ID: 18380893
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Investigating AP-2 and YY1 protein expression as a cause of high HER2 gene transcription in breast cancers with discordant HER2 gene amplification.
    Powe DG; Akhtar G; Habashy HO; Abdel-Fatah T; Rakha EA; Green AR; Ellis IO
    Breast Cancer Res; 2009; 11(6):R90. PubMed ID: 20025767
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prognostic Factors for Luminal B-like Breast Cancer.
    Ding NH; Liu CF; Hu C; Yuan JQ; Liao WH; Xiao Z
    Curr Med Sci; 2019 Jun; 39(3):396-402. PubMed ID: 31209809
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Power of PgR expression as a prognostic factor for ER-positive/HER2-negative breast cancer patients at intermediate risk classified by the Ki67 labeling index.
    Kurozumi S; Matsumoto H; Hayashi Y; Tozuka K; Inoue K; Horiguchi J; Takeyoshi I; Oyama T; Kurosumi M
    BMC Cancer; 2017 May; 17(1):354. PubMed ID: 28532429
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Molecular profiling of breast cancer in Nigerian women identifies an altered p53 pathway as a major mechanism underlying its poor prognosis compared with British counterpart.
    Agboola AO; Banjo AA; Anunobi CC; Ayoade BA; Deji-Agboola AM; Musa AA; Abdel-Fatah T; Nolan CC; Rakha EA; Ellis IO; Green AR
    Malays J Pathol; 2014 Apr; 36(1):3-17. PubMed ID: 24763230
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinicopathologic Characteristics of Oestrogen Receptor-Positive/Progesterone Receptor-Negative/Her2-Negative Breast Cancer According to a Novel Definition of Negative Progesterone Receptor Status: A Large Population-Based Study from China.
    Li AQ; Zhou SL; Li M; Xu Y; Shui RH; Yu BH; Yang WT
    PLoS One; 2015; 10(5):e0125067. PubMed ID: 25938238
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Inference of the Basal epithelial phenotype in breast carcinoma from differential marker expression, using tissue microarrays in triple negative breast cancer and women younger than 35.
    Nassar A; Sussman ZM; Lawson D; Cohen C
    Breast J; 2012 Sep; 18(5):399-405. PubMed ID: 22882580
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The biological, clinical and prognostic implications of p53 transcriptional pathways in breast cancers.
    Abdel-Fatah TM; Powe DG; Agboola J; Adamowicz-Brice M; Blamey RW; Lopez-Garcia MA; Green AR; Reis-Filho JS; Ellis IO
    J Pathol; 2010 Mar; 220(4):419-34. PubMed ID: 20044801
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long-Term Outcomes of Immunohistochemically Defined Subtypes of Breast Cancer Less Than or Equal to 2 cm After Breast-Conserving Surgery.
    Pata G; Guaineri A; Bianchi A; Amoroso V; Pasinetti N; Pasini M
    J Surg Res; 2019 Apr; 236():288-299. PubMed ID: 30694768
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The combined expression of solute carriers is associated with a poor prognosis in highly proliferative ER+ breast cancer.
    El-Ansari R; Craze ML; Alfarsi L; Soria D; Diez-Rodriguez M; Nolan CC; Ellis IO; Rakha EA; Green AR
    Breast Cancer Res Treat; 2019 May; 175(1):27-38. PubMed ID: 30671766
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Impact of estrogen receptor (ER) and human epidermal growth factor receptor-2 (HER2) co-expression on breast cancer disease characteristics: implications for tumor biology and research.
    Alqaisi A; Chen L; Romond E; Chambers M; Stevens M; Pasley G; Awasthi M; Massarweh S
    Breast Cancer Res Treat; 2014 Nov; 148(2):437-44. PubMed ID: 25257728
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.